10 license in/out transactions for domestic pharmaceutical companies in June

In June 2021, according to incomplete statistics from the Shell Society, a total of 9 license in transactions and 1 license out transaction occurred among domestic pharmaceutical companies.

Among them, Gaocheng Biotechnology licensed out 3 anti-tumor drugs, with a transaction amount of US$1.

From the perspective of transaction items, the research and development of new drugs is still dominated by anti-tumor and anti-infective drugs

License in/out transactions of domestic pharmaceutical companies in June 2021

Shell Club Drawing

The following is the specific situation of the license in/out transactions of domestic pharmaceutical companies in June:

1.

Introducer: Xinda Biological

On June 1, Cinda Biotech announced that it had reached a cooperation with Baoyuan Pharmaceutical.

According to the agreement, Baoyuan Pharmaceutical can obtain up to 189 million U.

It is reported that taletrectinib is a next-generation tyrosine kinase inhibitor targeting ROS1 and NTRK under development.

02.

Introducer: Zai Lab

On June 1, Zai Lab announced that it has reached a cooperation with Mirati Therapeutics (Mirati), and Zai Lab has obtained the right to develop and exclusively commercialize Adagrasib in Greater China (Mainland China, Hong Kong, Macau and Taiwan)

According to the agreement, Mirati will receive an upfront payment of US$65 million and up to US$273 million in additional development, regulatory and sales milestone payments

It is reported that Adagrasib is a research, highly selective and potent oral small molecule KRASG12C inhibitor.

03.

Introducer: Huadong Medicine

On June 1, Huadong Medicine announced that it has signed a strategic deployment agreement with SCOHIA PHARMA.
Huadong Medicine has obtained the exclusive development, production and commercialization rights of SCOHIA PHARMA's product SCO-094 in the Asia-Pacific region (25 countries and regions except Japan) , Used to treat endocrine diseases such as type 2 diabetes, obesity, non-alcoholic steatohepatitis
.

According to the agreement, SCOHIA PHARMA will receive a down payment of US$4 million, up to US$24 million in potential development, registration and commercialization milestones and tiered net sales commissions
.

It is reported that SCO-094 is a dual-target agonist of GLP-1 and GIP receptors, which can stimulate downstream pathways to produce biological effects such as blood sugar control and weight loss, and simultaneously exert the advantages of two targets to play a dual role Effect
.
At present, SCO-094 is carrying out a phase 1 clinical trial for type 2 diabetes indications in the UK.
Huadong Medicine will start clinical trials for SCO-094 product type 2 diabetes, weight loss and other indications in China as soon as possible after the transaction is completed
.

04.
Drug name: LYR-210

Authorized party: Lyra Therapeutics

Introducer: Liantuo Bio

On June 2, Liantuo Biotech announced that it has reached a strategic cooperation and exclusive license agreement with Lyra Therapeutics (LYRA).
The two parties will work together in Greater China (Mainland China and Hong Kong, Macao and Taiwan), South Korea, Singapore and Thailand to carry out LYR-210 Development and commercialization
.
As part of the agreement, Lantuo Bio will also obtain the priority right to develop and commercialize LYR-220 in the licensed area
.

Under the agreement, LYRA will receive a down payment of US$12 million and is eligible for development, regulatory and commercialization milestone payments of up to US$135 million
.
In addition, LYRA can also obtain LYR-210's low double-digit tiered sales share in each authorized region
.

It is reported that LYR-210 is a candidate product developed based on LYRA's unique XTreo™ platform, which can provide chronic sinusitis patients with local anti-inflammatory treatment for up to 6 months through a single treatment
.
LYR-220 is an intranasal anti-inflammatory drug base for the treatment of patients who have undergone sinus surgery but still have persistent sinusitis
.

05.
Drug name: NK cell therapy

Authorized party: Shoreline Biosciences

Introducer: BeiGene

On June 9, BeiGene announced an exclusive global strategic cooperation with Shoreline Biosciences (Shoreline).
Both parties will use Shoreline’s iPSC NK cell technology and BeiGene’s preclinical R&D and clinical development capabilities to develop and commercialize a series of The product portfolio of NK cell therapy is used to treat various malignant tumors
.
Among them, BeiGene will take the lead in global clinical development, and Shoreline will be responsible for clinical production
.

According to the agreement, Shoreline will receive a cash advance of US$45 million and is eligible to receive R&D funding, milestone payments and royalties when specific R&D, registration, and commercialization milestones are reached
.

It is reported that Shoreline's NK cell and macrophage therapy aims to become an efficient solution that targets and kills tumor tissues and restores tissue homeostasis
.
It is being used to develop drug candidates for a series of indications such as cancer, inflammation, and genetic diseases
.

06.
Drug name: ensifentrine

Authorized party: Verona Pharma

Introduced party: Yourui Pharmaceutical

On June 10, Yourui Pharmaceuticals announced an agreement with Verona Pharma (Verona).
Yourui Pharmaceuticals has obtained the development and commercialization rights of Verona's new drug ensifentrine in Greater China
.

According to the agreement, Verona can obtain a down payment of US$25 million and Urui Biotech (the parent company of Urui Medicine) currently worth approximately US$15 million of equity
.
In addition, Verona is entitled to up to US$179 million in milestone payments (including clinical, regulatory and commercial milestones, etc.
) in the future, and double-digit tiered royalties calculated as a percentage of ensifentrine’s net sales in Greater China
.

It is reported that ensifentrine is a phosphodiesterase protein (PDE3/PDE4) inhibitor that can simultaneously achieve bronchodilation and anti-inflammatory effects
.
Verona is currently conducting a global phase III clinical trial to evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD)
.

07.
Drug Name: Double Antibody

Authorized party: MacroGenics

Introducer: Zai Lab

On June 16, Zai Lab announced that it has reached a strategic cooperation with MacroGenics, and Zai Lab has obtained the development, production and commercialization rights of MacroGenics 4 bispecific molecules in Asia or globally
.

According to the agreement, MacroGenics can obtain an advance payment of US$25 million and an equity investment of US$30 million
.
In addition, MacroGenics will be eligible to receive potential development, registration and commercialization milestone payments and royalties in cooperation areas
.

The first project of this collaboration is a bispecific molecule developed through MacroGenics' DART® platform.
This target is expressed in a variety of solid tumors
.
As a new generation of DART® bispecific molecules, it will minimize cytokine release syndrome while maintaining anti-tumor cell activity
.
The second cooperation project will be selected by MacroGenics
.
Zai Lab will own the commercialization rights of these two products under development in Greater China, Japan and South Korea
.
In addition, Zai Lab has also obtained the exclusive license for global development, production and commercialization of two other MacroGenics research projects
.

08.
Drug name: AC-1101

Authorized party: Ancheng Biotechnology

Introducer: Chuangxiang Bio

On June 28, Chuangxiang Biotechnology and Ancheng Biotechnology announced a cooperation.
Among them, Chuangxiang Biotechnology granted the exclusive joint development right of its new drug AC-1101 to Chuangxiang Biotechnology to adapt to a selected skin disease.
Global Phase Ib clinical research is carried out during the symptom
.
If the preset conditions are met, Chuangxiang Bio will have the right to further develop, produce and commercialize the drug candidate in China and South Korea
.
In addition, under the premise of meeting preset conditions, Chuangxiang Bio will have the right to extend the scope of its rights to the world (excluding Taiwan)
.

According to the agreement, Ancheng Biotechnology will be entitled to a milestone fee of up to 126 million U.
S.
dollars and a sales milestone fee of up to 295 million U.
S.
dollars, as well as up to a double-digit annual net sales share after commercialization
.

It is reported that AC-1101 is a JAK targeted therapy with the potential to treat a variety of skin diseases, and has entered Phase 1 clinical trials
.

09.
Drug name:

Varoglutamstat, PBD-C06

Authorized party: Vivoryon Therapeutics

Introducer: Simcere Pharmaceutical

On June 29, Simcere Pharmaceuticals and Vivoryon Therapeutics reached a strategic regional licensing cooperation.
Simcere Pharmaceuticals can obtain the development and commercialization rights of two Alzheimer's disease (AD) drugs from Vivoryon Therapeutics in Greater China
.

It is reported that Varoglutamstat is an oral small molecule inhibitor of glutamyl peptide cyclase (QPCT)
.
Among them, QPCT can catalyze the production of N3pE amyloid, and this protein is not only related to the β amyloid peptide that is widely observed in AD patients, but also has an adverse effect on other pathological factors of AD, including tau pathology.
Performance, neuroinflammation, and synaptic function are impaired
.
Varoglutamstat plays a role in the early stage of disease pathogenesis by preventing the formation of this toxic variant, so it has the potential to prevent neuronal damage and is currently in the clinical phase 2 development stage
.

PBD-C06 is a humanized, deimmunized IgG1 antibody drug in the pre-clinical development stage, which can bind and remove N3pE amyloid in the brain, while having low immunogenicity and low ARIA inducing efficacy
.
Therefore, PBD-C06 can reduce the serious side effects of antibody drugs in the treatment of AD
.

2.
License out

Drug name: Galectin-9, CXCR5, CCR8

Authorized party: Gaocheng Biological

Introducer: FibroGen

On June 17, Gaocheng Biotech announced a cooperation with FibroGen
.
FibroGen has obtained the exclusive license for the Galectin-9 project of Gaocheng Biotechnology, and the exclusive right to license the development, production and commercialization of the CXCR5 and CCR8 projects
.

According to the agreement, Gaocheng Bio will receive a down payment of US$25 million and a milestone payment of up to US$1.
1 billion for the exercise of options, clinical, registration and commercialization of these three projects
.
In addition, Gaocheng Bio will also receive royalties based on global net sales of products
.

It is reported that Galectin-9 can inhibit anti-tumor immunity against myeloid malignancies and solid tumors.
The lead candidate antibody for the Galectin-9 project is expected to enter the clinical development stage in the first quarter of 2023
.
The CXCR5 and CCR8 projects can be used for tumors and autoimmune diseases.
The lead candidate antibodies related to the CXCR5 and CCR8 projects are expected to enter the clinical development stage in the middle of 2023
.